Lomedia 24 Fe
Marketed by: Amneal Pharmaceuticals
Compare to: Loestrin 24 Fe (Warner Chilcott)
Indication: Amneal Pharmaceuticals has launched Lomedia 24 Fe, an AB-rated generic equivalent to Warner Chilcott’s discontinued Loestrin 24 Fe. Lomedia 24 Fe will contain norethindrone acetate and ethinyl estradiol 1 mg/20 mcg and ferrous fumarate 75 mg. It is indicated for prevention of pregnancy in women who elect to use oral contraceptives.
Dosage Form: Tablets: 1 mg/20 mcg, 75 mg
For More Information: www.amneal.com; http://www.amneal.com/Docs/Lomedia_24_Fe_PI_Rev_10-2013.pdf
Rabeprazole Sodium Delayed-Release Tablets
Marketed by: Teva Pharmaceuticals
Compare to: Aciphex Delayed-Release Tablets (Eisai Inc)
Indication: Teva Pharmaceuticals announces the introduction and availability of rabeprazole sodium delayed-release tablets, an AB-rated bioequivalent to Aciphex Delayed-Release tablets. It is a proton-pump inhibitor indicated for the healing of erosive or ulcerative gastroesophageal reflux disease (GERD), maintenance of healing of erosive or ulcerative GERD, treatment of symptomatic GERD, healing of duodenal ulcers, Helicobacter pylori eradication to prevent duodenal ulcers, and treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
Dosage Form: Tablets: 20 mg
For More Information: www.tevagenerics.com
Oxymorphone Hydrochloride Extended Release Tablets
Marketed by: Actavis Inc
Compare to: Opana ER (Endo Health Solutions)
Indication: Actavis Inc has launched oxymorphone hydrochloride extended-release tablets, a generic equivalent to the previously marketed formulation of Endo Health Solutions’ Opana ER. Oxymorphone hydrochloride extended-release tablets are indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. The tablets will join Actavis’ already marketed oxymorphone hydrochloride tablets in 7.5- and 15-mg strengths.
Dosage Form: Extended-release tablets: 5, 10, 20, 30, and 40 mg
For More Information: www.actavis.com
Tetracylcline HCL Capsules, USP
Marketed by: Heritage Pharmaceuticals Inc
Compare to: Achromycin V (Lederle Laboratories)
Indication: Heritage Pharmaceuticals Inc announces the immediate availability of tetracycline HCl capsules, an AB-rated generic equivalent to Achromycin V. It is indicated for the treatment of bacterial infections due to organisms including Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae, Chlamydia psittaci, and Chlamydia trachomatis. For adults, the usual daily dose is either 500 mg twice daily or 250 mg 4 times daily, but higher doses may be recommended for severe infections or infections that do not respond to smaller doses.
Dosage Form: Capsules: 250 and 500 mg
For More Information: www.heritagepharma.com